• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Lindenboom Christine

    10/24/22 4:52:23 PM ET
    $ADGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Lindenboom Christine

    (Last) (First) (Middle)
    C/O INVIVYD, INC.
    1601 TRAPELO ROAD, SUITE 178

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Invivyd, Inc. [ IVVD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/20/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $3.67 10/20/2022 A 150,000 (1) 10/19/2032 Common Stock 150,000 $0.00 150,000 D
    Explanation of Responses:
    1. This option was granted on October 20, 2022 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the shares subject to the grant vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service through each vesting date.
    Remarks:
    /s/ Jill Andersen attorney-in-fact for Christine Lindenboom 10/24/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADGI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADGI

    DatePrice TargetRatingAnalyst
    1/6/2022$11.00 → $6.00Equal-Weight → Underweight
    Morgan Stanley
    1/6/2022Overweight → Underweight
    Morgan Stanley
    12/22/2021$46.00 → $10.00Buy → Hold
    Jefferies
    12/15/2021$49.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    12/15/2021Buy → Neutral
    Guggenheim
    12/15/2021$50.00 → $9.00Buy → Hold
    Stifel
    11/29/2021$49.00Equal-Weight → Overweight
    Morgan Stanley
    8/31/2021$33.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ADGI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Invivyd to Participate at Cowen's 43rd Annual Healthcare Conference

      WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced David Hering, chief executive officer of Invivyd, is scheduled to present at Cowen's 43rd Annual Healthcare Conference on Monday, March 6, 2023 at 2:10 p.m. ET. A live webcast of the presentation will be available in the investor section of the company's website at investors.invivyd.com and will be archived for 90 days following the presentation. About Invivyd(NASDAQ:IVVD)Invivyd, Inc., formerly Adagio Therapeutics (NASDAQ:ADGI), is a biopharmaceutical company on a mission to prot

      2/28/23 7:00:00 AM ET
      $IVVD
      $ADGI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Invivyd Announces Changes to Executive Team

      WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical stage biopharmaceutical company on a mission to protect humanity from serious infectious diseases, today announced that Laura Walker, Ph.D., the company's chief scientific officer and co-founder, decided to leave the company to pursue other opportunities. The management team has initiated a search process to identify her replacement. Until a permanent successor is named, Invivyd team member Lukas Dillinger, Ph.D., has been appointed as interim Head of Discovery and Pre-Clinical. "On behalf of the company, I extend my gratitude and thanks for Laura's scientific passion and contributions that led to

      2/3/23 7:30:00 AM ET
      $IVVD
      $ADGI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

      WALTHAM, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, was invited to participate in an FDA-EMA workshop on SARS-CoV-2 monoclonal antibodies held on December 15, 2022. Invivyd's chief scientific officer, Laura Walker, Ph.D., alongside Eli Lilly and Company and Regeneron Pharmaceuticals, Inc., presented a joint industry approach for anti-spike monoclonal antibody development to keep pace with SARS-CoV-2 variants. The meeting featured presentations by scientists, clinicians, regulators, and industry representatives to discuss alternative strategies to s

      12/19/22 7:00:00 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Adagio Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Adagio Therapeutics from Equal-Weight to Underweight and set a new price target of $6.00 from $11.00 previously

      1/6/22 8:13:15 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Adagio Therapeutics from Overweight to Underweight

      1/6/22 7:59:18 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Adagio Therapeutics from Buy to Hold and set a new price target of $10.00 from $46.00 previously

      12/22/21 5:36:31 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Dabora Rebecca

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:20:29 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Andersen Jill

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:16:35 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Schmidt Peter

      4 - Invivyd, Inc. (0001832038) (Issuer)

      12/16/22 5:14:31 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Leadership Updates

    Live Leadership Updates

    See more
    • Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

      WALTHAM, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Jeremy Gowler as chief operating and commercial officer, effective December 16, 2022, and the promotion of Pete Schmidt, M.D. to chief medical officer, effective immediately. In his new role Mr. Gowler will oversee operations and commercial activities for the company. Dr. Schmidt will be responsible for overseeing all medical, clinical development and regulatory activities at Invivyd. Dr. Ellie Hershberger, Invivyd's chief development officer, is departing f

      12/6/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

      WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Christine Lindenboom, senior vice president investor relations & corporate communications at Alnylam Pharmaceuticals, Inc., to its board of directors. In addition, Redonda Miller, M.D., M.B.A., president of The Johns Hopkins Hospital, has stepped down from her position on the board. "We are excited to welcome Christine to our board of directors where her business acumen and deep knowledge of the biopharmaceutical industry will round out and enhance our current b

      10/24/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

      WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced the appointment of Fred Driscoll as interim CFO as well as headcount changes to align resources to its key programs. The changes are designed to improve capital efficiency by reallocating resources to programs and functions to support our key activities on an accelerated timeline. As part of the resource realignment, the company is building out additional discovery and early development positions and has eliminated several corporate and commercial positions, among others, to execute effi

      10/13/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      8/19/22 5:22:28 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      7/5/22 8:11:01 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adagio Therapeutics Inc. (Amendment)

      SC 13D/A - Adagio Therapeutics, Inc. (0001832038) (Subject)

      6/24/22 5:10:52 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    Financials

    Live finance-specific insights

    See more
    • Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

      Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support operating runway into Q2 2024 Conference call scheduled for Thursday, November 10th at 4:30 p.m. ET WALTHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022. "It has been a productive quarter starting with a corporate rebrand emphasizing our commitment to e

      11/10/22 4:01:00 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

      WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced that it will host a conference call on Thursday, November 10, 2022, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2022, and recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan o

      11/2/22 7:00:00 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADGI
    SEC Filings

    See more
    • Adagio Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Invivyd, Inc. (0001832038) (Filer)

      1/9/23 7:11:01 AM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adagio Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Invivyd, Inc. (0001832038) (Filer)

      12/6/22 4:28:56 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Adagio Therapeutics Inc.

      D - Invivyd, Inc. (0001832038) (Filer)

      11/29/22 5:16:38 PM ET
      $ADGI
      Biotechnology: Pharmaceutical Preparations
      Health Care